mTOR inhibitors: all 1,276 studies that test it
Page 8 of 13. Open to participants first (126), then studies with results posted, then the rest; newest registration first within each.
- TB Host Directed TherapyStatus unknownNCT02968927Phase 2
- Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued TreatmentActive, not recruitingNCT02962414Phase 3
- Topical Everolimus in Patients With Tuberous Sclerosis ComplexWithdrawnNCT02860494Phase 2/3
- Sirolimus and Cyclophosphamide in Metastatic or Unresectable Myxoid Liposarcoma and ChondrosarcomaCompletedNCT02821507Phase 2
- Omental Islet TransplantCompletedNCT02821026Phase 1/2
- Single-centre Study of Everolimus as GvHD Prophylaxis After Post-Transplantation Cyclophosphamide After Allogeneic SCTCompletedNCT02812940Phase 2
- Monotherapy With Rapamycin in Long-standing Type 1 DiabetesCompletedNCT02803892Phase 2
- A Study of Rapamycin Combined With Intravesical BCG in Patients With Non-muscle Invasive Bladder CancerCompletedNCT02753309Early Phase 1
- A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast CancerCompletedNCT02742051Phase 2
- Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCTTerminatedNCT02728700Phase 1
- Adjuvant Anti-Recurrence Treatment With Rapamycin on Early-stage HCCCompletedNCT02724332Phase 1
- Cisplatinum and Everolimus in Patients With Metastatic or Unresectable NEC of Extrapulmonary OriginStatus unknownNCT02695459Phase 2
- Study to Evaluate the Safety and Efficacy of Sirolimus, in Subject With Refractory Solid TumorsCompletedNCT02688881Phase 4
- Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic OriginActive, not recruitingNCT02687958Phase 2
- Study Comparing Efficacy and Safety of Mycophenolate Mofetil (Cellcept) With Delayed Introduction of Sirolimus and Discontinuation of Cyclosporine, With Those of Mycophenolate Mofetil and Long Term Continuation of Cyclosporine in Renal Transplant RecipientsCompletedNCT02686619Phase 3
- Sirolimus Associated With Tacrolimus at Low Doses in Elderly Kidney Transplant PatientsCompletedNCT02683291Phase 4
- Nonmyeloablative Conditioning for Mismatched Hematopoietic Stem Cell Transplantation for Severe Sickle Cell DiseaseTerminatedNCT02678143Phase 1
- To Evaluate the Efficacy and Safety of Rapamycin for Crohn's Disease-related StrictureStatus unknownNCT02675153Not applicable
- Conversion to Sirolimus: Effects in Cytomegalovirus Infection RecurrenceStatus unknownNCT02671318Phase 4
- Genomics-Based Target Therapy for Children With Relapsed or Refractory MalignancyStatus unknownNCT02638428Phase 2
- High Dose Peripheral Blood Stem Cell Transplantation With Post Transplant Cyclophosphamide for Patients With Chronic Granulomatous DiseaseActive, not recruitingNCT02629120Phase 1/2
- Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast CancersStatus unknownNCT02616848Phase 1
- Prospective Pilot Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-grade PineoblastomaCompletedNCT02596828Phase 2
- Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS TumorsActive, not recruitingNCT02574728Phase 2
- Open Label Study of Everolimus (RAD001) in Patients With Segmental Overgrowth SyndromeWithdrawnNCT02569125Phase 2
- Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast CancerCompletedNCT02531932Phase 2
- Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With MyelofibrosisWithdrawnNCT02528877Phase 1
- Sirolimus for the Treatment of HyperinsulinismWithdrawnNCT02524639Phase 1/2
- Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer PatientsCompletedNCT02511639Phase 3
- suPERficial Slow-flow Vascular malFORMations Treated With sirolimUSCompletedNCT02509468Phase 2
- Minimal Islet Transplant at Diabetes OnsetCompletedNCT02505893Phase 2
- Effects of Everolimus in Left Ventricular Hypertrophy After Conversion From Azathioprine: A Pilot StudyStatus unknownNCT02493465Phase 4
- Rapamycine vs Placebo for the Treatment of Inclusion Body MyositisCompletedNCT02481453Phase 2/3
- PRednisone Plus EVerolimus in Patients With Metastatic Renal Cell Cancer After Failure of VEGFR -TKITerminatedNCT02479490Phase 2
- The Pilot Study Evaluate the Safety and Efficacy of Sirolimus in Patients With PIK3CA Mutation and/or PIK3CA Amplification Refractory Solid TumorsCompletedNCT02449564Not applicable
- Study to Evaluate the Safety and Efficacy of Everolimus, in Subjects With PIK3CA Amplification, PTEN Loss and PIK3CA Mutation Refractory Solid TumorsCompletedNCT02449538Phase 2
- Sirolimus Effect on Hypertrophic Syndromes Related Gene PIK3CACompletedNCT02443818Phase 2
- Trial With Gemcitabine and Rapamycin in Second Line of Metastatic OsteosarcomaCompletedNCT02429973Phase 2
- Vorinostat and Temsirolimus With or Without Radiation Therapy in Treating Younger Patients With Newly Diagnosed or Progressive Diffuse Intrinsic Pontine GliomaCompletedNCT02420613Phase 1
- Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast CancerStatus unknownNCT02404051Phase 3
- Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial CancerActive, not recruitingNCT02397083Phase 2
- Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid TumorsActive, not recruitingNCT02389309Phase 1
- Systemic Rapamycin (Sirolimus) to Prevent In-Stent Restenosis Following Pulmonary Artery Stent PlacementWithdrawnNCT02365415Phase 2
- Study of GnRH-A [Leuprorelin(Lorelin Depot] Plus Leterozole +/- Everolimus for Premenopausal Women With Metastatic Breast CancerCompletedNCT02344550Phase 2
- Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS TumoursCompletedNCT02343718Phase 1
- Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE)TerminatedNCT02338570Phase 4
- Combination of Everolimus and Octreotide LAR in Aggressive Recurrent MeningiomasCompletedNCT02333565Phase 2
- Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine ACompletedNCT02328963Phase 4
- Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung CancerActive, not recruitingNCT02321501Phase 1
- Efficacy and Safety of Everolimus in de Novo Kidney Transplant Recipients of ECD or AKI DonorsStatus unknownNCT02314312Phase 3
- Everolimus trIal for Advanced prememopausaL Breast Cancer PatientsStatus unknownNCT02313051Phase 2
- A Biological Prospective Study in Patients With Metastatic Pancreatic NETs Treated With EverolimusCompletedNCT02305810Phase 2
- Bioavailability Study of Sirolimus Tablets 2 mg Under Fed ConditionCompletedNCT02296762Phase 1
- Bioavailability Study of Sirolimus Tablets 2 mg Under Fasting ConditionCompletedNCT02296749Phase 1
- Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin LymphomaTerminatedNCT02254239Phase 1
- Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With BevacizumabCompletedNCT02248571Phase 4
- Everolimus and Temozolomide in Advanced Gastroenteropancreatic Neuroendocrine Carcinoma (G3)CompletedNCT02248012Phase 2
- Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic CancerCompletedNCT02240719Phase 1
- Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) EradicationStatus unknownNCT02233049Phase 2
- Temsirolimus and Cetuximab in Patients With Advanced or Metastatic Solid TumorsCompletedNCT02215720Phase 1
- Treatment of Port Wine Stains Using Pulsed Dye Laser, Erbium Yag Laser and Topical SirolimusTerminatedNCT02214706Not applicable
- Effects of the Quadruple Immunosuppression on Peripheral Blood Lymphocytes and Development of Anti-HLA Antibodies in Kidney TransplantStatus unknownNCT02208791Phase 4
- An Open Label, Single-Centre, Pilot Study of Everolimus With EBRT for the Treatment of mNET Liver MetastasisCompletedNCT02205515Phase 1/2
- Sirolimus Prophylaxis for aGVHD in TME SCIDWithdrawnNCT02177760Phase 2
- Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive PatientsCompletedNCT02152943Phase 1
- The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted RecipientsCompletedNCT02134899Phase 3
- Belatacept for Renal Transplant Recipients With Delayed Graft FunctionTerminatedNCT02134288Early Phase 1
- Auranofin and Sirolimus in Treating Patients With Advanced Solid Tumors or Recurrent Non-Small Cell Lung CancerWithdrawnNCT02126527Phase 1
- Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate CancerCompletedNCT02125084Phase 1
- Calcineurin Inhibitor Based Immunosuppression WithdrawalCompletedNCT02117596Not applicable
- Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II StudyCompletedNCT02113800Phase 2
- Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With ExemestaneStatus unknownNCT02109913Not applicable
- POEM STUDY: A Phase IIa Trial in Endometrial Carcinoma With TemsirolimusCompletedNCT02093598Phase 2
- MicroRNA Expression in Everolimus-based Versus Tacrolimus-based Regimens in Kidney TransplantationStatus unknownNCT02091973Not applicable
- Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal TransplantCompletedNCT02084446Phase 4
- Efficacy and Safety Study of Topical Rapamycin Associated With Pulsed Dye Laser in Patients With Sturge-Weber SyndromeCompletedNCT02080624Phase 2
- Effect of Everolimus on the Pharmacokinetics of Tacrolimus in Renal Transplant PatientsCompletedNCT02077556Phase 4
- Differentiating Everolimus Versus Sirolimus in Combination With Calcineurin Inhibitors in Kidney Transplant PatientsWithdrawnNCT02062892Phase 4
- Everolimus in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab TreatmentCompletedNCT02056587Phase 4
- Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney DiseaseStatus unknownNCT02055079Phase 3
- Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With ChemotherapyCompletedNCT02049047Phase 2
- Evaluate Efficacy Study of Combination Therapy of Everolimus and Low Dose Tacrolimus in Renal Allograft RecipientsStatus unknownNCT02036554Phase 4
- Pet Imaging as a Biomarker in Hormone Refractory postmenopausaL WomenCompletedNCT02028364Phase 2
- Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast CancerStatus unknownNCT02025712Phase 2
- Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain TumorsStatus unknownNCT02015728Not applicable
- A Pilot Study of Genomic Sequencing Guided Individualized Therapy in Gastrointestinal Cancers, GITIC StudyStatus unknownNCT02013089Not applicable
- A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed ChondrosarcomasSuspendedNCT02008019Phase 2
- Everolimus Post Orthotopic Liver TransplantStatus unknownNCT01998789Phase 2
- Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS)WithdrawnNCT01997255Phase 2
- Everolimus in Selected Patients With Metastatic Melanoma: Efficacy and Safety StudyStatus unknownNCT01960829Phase 2
- Study Comparing in Livertransplantation Recipients With Tacrolimus Alone Versus Tacrolimus&SirolimusCompletedNCT01958190Phase 4
- A Study of Everolimus in the Treatment of Neurocognitive Problems in Tuberous SclerosisStatus unknownNCT01954693Phase 2
- Phase Ib/II Trials of RAD001 in Triple Negative Metastatic Breast CancerTerminatedNCT01939418Phase 1/2
- Evaluation of Early Use of Everolimus (EVE) on Cytomegalovirus (CMV) Infection in Renal Transplant RecipientsStatus unknownNCT01927588Phase 4
- Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin LymphomaCompletedNCT01902160Phase 1
- Cardiac Allograft Remodeling and Effects of SirolimusTerminatedNCT01889992Phase 1
- Sirolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients At High Risk for Cholangiocarcinoma Recurrence After Liver Transplant or SurgeryCompletedNCT01888302Phase 1
- Assessing Everolimus in Fist Line Treatment on Patients With Metastatic Kidney CancerTerminatedNCT01888042Phase 2
- Exploring the Activity of RAD001 in Vestibular Schwannomas and MeningiomasCompletedNCT01880749Early Phase 1
- Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant DiseaseWithdrawnNCT01864070Phase 1